Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Trine Hørmann Thomsen, Nick Schou Nielsen, Asher Lou Isenberg, Michael Hougaard Møller, Jesper Bøje Clausen, Inge Mona Schack Frederiksen, Louise Olsen, Mahsa Javidi, Jeanet Vilhelmsen, Marc Klee Olsen, Bo Biering-Sørensen
BACKGROUND: Testing and titration of the right levodopa equivalent dose are usually performed during a hospital admission. However, optimal dose titration in people with Parkinson's disease (PwPs) may depend on home environment, emotional stress, and physical activity of everyday life. OBJECTIVE: Firstly, to evaluate the feasibility and safety of a home-based LCIG titration program and patients'/caregivers' satisfaction. Secondly, to identify barriers and facilitators for home-based titration...
2024: Parkinson's Disease
#2
REVIEW
Nils Schröter, Bastian E A Sajonz, Wolfgang H Jost, Michel Rijntjes, Volker A Coenen, Sergiu Groppa
Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep brain stimulation (DBS) are used to treat Parkinson's disease with insufficient symptom alleviation under intensified pharmacotherapy. These DAT significantly differ in their efficacy profiles, indication, invasiveness, contraindications, and potential side effects...
April 13, 2024: Journal of Neural Transmission
#3
JOURNAL ARTICLE
John P Savaryn, Richard L Smith, Matthew Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David Wagner
Analysis was conducted to compare levodopa/carbidopa pharmacokinetics and drug-related material in plasma of healthy participants after receiving a continuous infusion of Levodopa/Carbidopa Intestinal Gel (LCIG) to a continuous subcutaneous infusion of foslevodopa/foscarbidopa. Study samples were from a randomized, open-label, 2-period crossover study in 20 healthy participants. Participants received either 24-h foslevodopa/foscarbidopa SC infusion to the abdomen or LCIG delivered for 24 h to the jejunum through a nasogastric tube with jejunal extension...
April 2024: Pharmacology Research & Perspectives
#4
JOURNAL ARTICLE
Vili Viljaharju, Tuomas Mertsalmi, K Amande M Pauls, Maija Koivu, Johanna Eerola-Rautio, Marianne Udd, Eero Pekkonen
BACKGROUND: Levodopa-entacapone-carbidopa intestinal gel (LECIG) is a novel device assisted treatment option for advanced Parkinson's disease (PD). It has been available in Finland since 2020. There is paucity of scientific studies considering LECIG treatment in clinical practice. OBJECTIVES: Objectives of this study were to evaluate the changes in medication, adverse events and early discontinuations of LECIG treatment in real life clinical practice. METHODS: The records of 30 consecutive patients, who received LECIG between years 2020 and 2022 in Helsinki University Hospital, were retrospectively analyzed...
February 2024: Movement Disorders Clinical Practice
#5
JOURNAL ARTICLE
Szabolcs Szatmári, József Attila Szász, Károly Orbán-Kis, Simona Bataga, Marius Ciorba, Előd Nagy, Radu Neagoe, István Mihály, Péter Zsombor Szász, Krisztina Kelemen, Attila Frigy, Andrea Csipor-Fodor, Viorelia Adelina Constantin
Continuous intra-jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is a long-term proven and effective treatment in advanced Parkinson's Disease (APD). Efficacy and safety of 16-h administration of LCIG has already been established. Additional benefits of 24-h LCIG administration have been reported in several case series and small clinical studies. The aim of this retrospective study was to compare the characteristics of patients who needed 24-h LCIG from the beginning of the DAT (device-aided treatment) with those who remained with the standard 16-h LCIG treatment and to identify particular motives if any...
February 14, 2024: Scientific Reports
#6
JOURNAL ARTICLE
Nils Schröter, Wolfgang H Jost, Michel Rijntjes, Volker Coenen, Sergiu Groppa, Bastian Sajonz
In the therapy of Parkinson̓s disease, both the intrajejunal administration of Levodopa/Carbidopa Intestinal Gel (LCIG) and, more recently, Levodopa/Carbidopa/Entacapone Intestinal Gel (LECIG), as well as deep brain stimulation (DBS), are employed. These approaches differ significantly in their efficacy and side effect profiles, as well as the timing of their use. Yet, the initiation of therapy for both methods is often simultaneously considered when patients have reached an advanced stage of the disease...
February 12, 2024: Fortschritte der Neurologie-Psychiatrie
#7
JOURNAL ARTICLE
Eric Freire-Alvarez, Paola Vanni, Egon Kurča, Lydia Lopez-Manzanares, Norbert Kovács, Cleanthe Spanaki, Tianming Gao, Lars Bergmann, Olga Sánchez-Soliño
INTRODUCTION: The DYSCOVER study was a phase 3b, open-label, randomized trial (NCT02799381) that evaluated levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) in patients with Parkinson's disease (PD) and a high burden of dyskinesia at baseline (defined as Unified Dyskinesia Rating Scale [UDysRS] total score ≥ 30). At week 12, patients receiving LCIG versus OMT experienced significant improvements in dyskinesia, pain, and health-related outcomes...
February 12, 2024: Neurology and Therapy
#8
JOURNAL ARTICLE
Kensuke Ikenaka, Yuta Kajiyama, César Aguirre, Chi-Jing Choong, Seira Taniguchi, Junko Doi, Nan Wang, Takahiro Ajiki, Kotaro Ogawa, Keita Kakuda, Yasuyoshi Kimura, Hideki Mochizuki
The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol-o-methyl-transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa-Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31)...
February 2024: Pharmacology Research & Perspectives
#9
JOURNAL ARTICLE
Noriyuki Miyaue, Yuko Ito, Yuki Yamanishi, Satoshi Tada, Rina Ando, Hayato Yabe, Masahiro Nagai
BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) treatment markedly reduces motor fluctuations in patients with Parkinson's disease; however, some patients undergoing LCIG treatment may demonstrate clinical deterioration in the afternoon. Entacapone, a catechol-O-methyltransferase inhibitor, may be a promising adjunctive option for LCIG-treated patients; however, the optimal timing of oral entacapone administration to ameliorate clinical symptoms in the afternoon remains unexplored...
February 15, 2024: Journal of the Neurological Sciences
#10
JOURNAL ARTICLE
George Umemoto, Shinsuke Fujioka, Yuki Iwashita, Yuriko Dotsu, Masako Noda, Yoshio Tsuboi
OBJECTIVE: Weight loss (WL) is the most common symptom among patients with Parkinson's disease (PD) and has been reported to start several years before the diagnosis of PD. The relationship between WL and PD treatment is complex. This study aimed to characterize the impact of PD treatment on WL and find clues to establish the administration of nutrition for patients with PD. MATERIALS AND METHODS: Eighty-two patients with PD (mean age, 58.4 ± 10.2 years; mean Hoehn and Yahr stage, 3...
January 2024: Clinical Neurology and Neurosurgery
#11
JOURNAL ARTICLE
Aya Kawanami, Masanobu Miyashita, Yuichi Miyagi, Kazuko Hasegawa
A 70-year-old male who has medical history of Parkinson's disease for 26 years admitted to our hospital for trial of levodopa carbidopa intestinal gel (LCIG) therapy because of severe dyskinesia and frequent wearing-off. He developed deterioration when he was treated with one of the levodopa (LD) decacrboxylase inhibitor compounds in the past. Five days after LD had changed into equivalent dose of LD/carbidopa (CD), high fever with hyperCKemia appeared. He was diagnosed as having Parkinsonism-hyperpyrexia syndrome (PHS)...
January 20, 2024: Rinshō Shinkeigaku, Clinical Neurology
#12
JOURNAL ARTICLE
Masatoshi Nakagawa, Noboru Inoue, Shuhei Takise, Masashi Takayanagi, Tsukasa Kubo, Hiroto Muroi, Masanobu Nakajima, Shinji Morita, Takatoshi Nakamura, Kazuyuki Kojima
BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) treatment is an effective Parkinson's disease (PD) treatment that requires percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J). Buried bumper syndrome (BBS) is an uncommon but significant complication of PEG-J for LCIG. Case presentation A 71-year-old man had been undergoing LCIG therapy for PD since a PEG-J was implemented at our department two years previously. He presented with appetite loss. Computed tomography showed that the gastrostomy bumper was buried in the gastric wall...
December 11, 2023: Surgical Case Reports
#13
JOURNAL ARTICLE
R Balestrino, T Martone, M Toffoli, E Montanaro, M Fabbri, C A Artusi, A Romagnolo, M Zibetti, M Rizzone, S Goldwurm, L Lopiano, A H V Schapira
BACKGROUND: Levodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment. There is some evidence to suggest that the genetic background may influence the clinical presentation and rate of progression of PD. Whether the genetic background influences the outcome of device-assisted therapies is currently debated. Some studies have investigated the effectiveness of deep brain stimulation (DBS) in PD patients with different genetic background, while evidence is lacking regarding LCIG...
November 6, 2023: Neurological Sciences
#14
JOURNAL ARTICLE
Dominik Pürner, Mohammad Hormozi, Daniel Weiß, Michael T Barbe, Hannah Jergas, Tino Prell, Eileen Gülke, Monika Pötter-Nerger, Björn Falkenburger, Lisa Klingelhöfer, Pia K Gutsmiedl, Bernhard Haslinger, Angela M Jochim, Andreas Wolff, Nils Schröter, Michel Rijntjes, Christoph van Riesen, Ute Scheller, Martin Wolz, Ali Amouzandeh, Georg Ebersbach, Doreen Gruber, Zacharias Kohl, Walter Maetzler, Steffen Paschen, Pablo Pérez-González, Verena Rozanski, Johannes Schwarz, Martin Südmeyer, Elisabeth Torka, Simone Wesbuer, Sarah Bornmann, Agnes Flöel, Chi Wang Ip, Patricia Krause, Andrea A Kühn, Ilona Csoti, Birgit Herting, Simone van de Loo, Aniz Ahammed Basheer, Robert Liszka, Wolfgang H Jost, Jiri Koschel, Bernhard Haller, Paul Lingor
BACKGROUND AND OBJECTIVES: Advanced therapies (ATs; deep brain stimulation [DBS] or pump therapies: continuous subcutaneous apomorphine infusion [CSAI], levodopa/carbidopa intestinal gel [LCIG]) are used in later stages of Parkinson disease (PD). However, decreasing efficacy over time and/or side effects may require an AT change or combination in individual patients. Current knowledge about changing or combining ATs is limited to mostly retrospective and small-scale studies. The nationwide case collection Combinations of Advanced Therapies in PD assessed simultaneous or sequential AT combinations in Germany since 2005 to analyze their clinical outcome, their side effects, and the reasons for AT modifications...
November 21, 2023: Neurology
#15
Atsushi Imamura, Gen Kuroyanagi, Takuya Usami, Toyohiro Sato, Mitsuya Horiba, Hiroaki Sakai, Ayaka Takahashi, Yoshino Ueki, Noriyuki Matsukawa, Hideki Murakami
BACKGROUND: Patients with Parkinson's disease have a high dislocation rate after total hip arthroplasty (THA). This study describes a case with severe Parkinson's disease who developed rapidly destructive coxarthrosis (RDC) and underwent THA using a dual mobility cup after a levodopa-carbidopa intestinal gel (LCIG) infusion. CASE PRESENTATION: The patient is a 59-year-old female with a ten-year history of Parkinson's disease, which was first treated with oral levodopa...
September 15, 2023: Orthopaedic Surgery
#16
REVIEW
Onanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Garcia-Ruiz, Per Odin, Peter Riederer, Thomas Müller
Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites...
August 21, 2023: Journal of Neural Transmission
#17
JOURNAL ARTICLE
Yusuke Nomoto, Makoto Furihata, Haruka Hagiwara, Hirotaka Ishino, Shintaro Yano, Hiroki Okawa, Yoichi Nakatsu, Kumiko Noda, Shinjiro Nishi, Shingo Ogiwara, Tsuneo Kitamura, Taro Osada
BACKGROUND Parkinson's disease (PD) is a neurodegenerative disorder that often requires long-term management of motor symptoms. Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) has shown promising results in alleviating motor fluctuations and improving quality of life. This study aimed to evaluate the efficacy and safety of transgastric jejunostomy (PEG-J) as a delivery method for LCIG in a cohort of 43 PD patients. MATERIAL AND METHODS Forty-three PD patients who were candidates for LCIG therapy underwent transgastric jejunostomy to facilitate continuous infusion of LCIG...
August 12, 2023: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
#18
REVIEW
Harmen R Moes, Tove Henriksen, Jarosław Sławek, Onanong Phokaewvarangkul, Erik Buskens, Teus van Laar
This article provides an overview of the various screening and selection tools which have been developed over the past 25 years to identify patients with Parkinson's disease (PD) possibly eligible for device-aided therapies (DATs). For the available screening tools, we describe the target therapies (subtypes of DAT), development methods, validation data, and their use in clinical practice. In addition, the historical background and potential utility of these screening tools are discussed. The challenges in developing and validating these tools are also addressed, taking into account the differences in population, the local health care organization, and resource availability...
July 27, 2023: Journal of Neural Transmission
#19
JOURNAL ARTICLE
Hugo Morales-Briceño, Ainhi D Ha, Han-Lin Chiang, Yicheng Tai, Florence C F Chang, David S Tsui, Jane Griffith, Donna Galea, Samuel D Kim, Belinda Cruse, Neil Mahant, Victor S C Fung
Comparative studies assessing outcomes with the three device-assisted therapies could help to individualise treatment for patients living with Parkinson's disease. We designed a single-centre non-randomised prospective observational study assessing the quality of life (QoL), motor and non-motor outcomes at 6 and 12-months in patients treated with subcutaneous apomorphine continuous 16-hours infusion (APO), levodopa-carbidopa intestinal gel (LCIG) or subthalamic nucleus deep brain stimulation (STN-DBS). In this study, 66 patients were included (13 APO; 19 LCIG; 34 STN-DBS)...
June 29, 2023: NPJ Parkinson's Disease
#20
REVIEW
Teus van Laar, K Ray Chaudhuri, Angelo Antonini, Tove Henriksen, Maja Trošt
Oral levodopa is the gold-standard therapy for treating Parkinson's disease (PD) but after a few years of treatment the therapeutic window narrows, and patients often experience various treatment-related complications. Patients in this advanced PD stage may benefit from alternative therapy, such as continuous intrajejunal delivery of levodopa-carbidopa intestinal gel (LCIG; or carbidopa-levodopa enteral suspension), continuous intrajejunal delivery of levodopa-carbidopa-entacapone intestinal gel, or continuous subcutaneous apomorphine infusion...
2023: Journal of Parkinson's Disease
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
